<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231851</url>
  </required_header>
  <id_info>
    <org_study_id>UCI 18-105 [HS# 2019-5533]</org_study_id>
    <secondary_id>2019-5533</secondary_id>
    <secondary_id>UCHMC1913</secondary_id>
    <nct_id>NCT04231851</nct_id>
  </id_info>
  <brief_title>CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia</brief_title>
  <official_title>Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in&#xD;
      combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic&#xD;
      syndrome related changes or therapy-related acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Event-Free Survival at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>This is defined as the percentage of subjects with event-free survival (EFS) at 6 months. EFS is defined as the number of months where patients are in a remission state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Grade 3-5 Adverse Events</measure>
    <time_frame>From the start date of treatment until 4 weeks after removal of treatment due to disease progression, toxicity, delay of treatment, or withdrawal of treatment, whichever came first, an average of 1 year.</time_frame>
    <description>To evaluate the tolerability of administering CPX-351 in combination with glasdegib in patients with newly diagnosed with Acute Myeloid Leukemia (AML) with Myelodysplastic Syndrome (MDS) related changes or treatment-related AML from the start of treatment, duration of treatment and up to 4 weeks after completion of study treatment. Toxicity and adverse events are based on the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>From the start date of treatment until first date of CR/CRi or an average of 1 year.</time_frame>
    <description>To assess the overall response rate to the combination of CPX-351 and glasdegib. The overall response rate (ORR) is defined as the rate of complete remissions (CR) and complete remission with incomplete count recovery (CRi). ORR = CR + CRi</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of Response</measure>
    <time_frame>From the start date of treatment until first date of CR/CRi or an average of 1 year.</time_frame>
    <description>Durability of response is measured by relapse-free survival (RFS). RFS is defined as the amount of time a patient remains in remission after having achieved a CR or CRi</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival of Patients who received the combination of CPX-351 and glasdegib</measure>
    <time_frame>Time from screening biopsy for up to 12 months after the last patient is enrolled or until death from any cause, whichever came first.</time_frame>
    <description>To evaluate the overall survival of patients with newly diagnosed with Acute Myeloid Leukemia (AML) with Myelodysplastic Syndrome (MDS) related changes or treatment-related AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to normal hematopoiesis as assessed by laboratory studies</measure>
    <time_frame>From the start date of treatment until laboratory studies confirmation of normal hematopoiesis or an average of 1 year</time_frame>
    <description>To evaluate the time to normal hematopoiesis, process by which blood cells are formed, as determined by laboratory studies inclusive of complete blood counts (CBCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who go on to receive an allogenic hematopoietic stem cell transplant</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>This is defined as the number of participants who continue on to receive an allogenic hematopoietic stem cell transplant after induction, re-induction, or consolidation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Myelogenous Leukemia (AML) Due to Therapy</condition>
  <condition>Acute Myeloid Leukemia With Myelodysplasia-Related Changes</condition>
  <arm_group>
    <arm_group_label>CPX-351 and Glasdegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Induction, subjects receive 44mg/m2/100mg/m2 IV on days 1, 3 and 5 and Glasdegib 100mg PO daily on days 6 to 28.&#xD;
If re-induction is needed: Subjects receive 44mg/m2/100mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.&#xD;
In consolidation: Subjects receive 29mg/m2/65mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.&#xD;
If maintenance is required, Subjects receive Glasdegib 100mg PO daily for up to one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glasdegib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>CPX-351 and Glasdegib</arm_group_label>
    <other_name>DAURISMO™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351</intervention_name>
    <description>Given IV</description>
    <arm_group_label>CPX-351 and Glasdegib</arm_group_label>
    <other_name>Daunorubicin and cytarabine</other_name>
    <other_name>VYXEOS®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously untreated therapy-related AML or AML with myelodysplastic related changes&#xD;
             as described by World Health Organization (WHO) 2016&#xD;
&#xD;
               1. AML arising in MDS (including CMML) or MDS/MPN syndrome&#xD;
&#xD;
               2. AML with MDS-related cytogenetic abnormalities (Appendix A, metaphase FISH&#xD;
                  allowable as surrogate for cytogenetics)&#xD;
&#xD;
               3. AML with multi-lineage dysplasia involving the presence of 50% or more dysplastic&#xD;
                  cells in at least two cell lines and in the absence of mutation in NPM1 or&#xD;
                  biallelic CEBPA (as per WHO 2016)&#xD;
&#xD;
          -  Adults 18 years of age or older&#xD;
&#xD;
          -  ECOG performance status 0 to 2&#xD;
&#xD;
          -  Adequate organ function as defined as:&#xD;
&#xD;
               1. Left Ventricular Ejection Fraction (LVEF) &gt; 50%&#xD;
&#xD;
               2. Serum total bilirubin &lt; 2.0 mg/dL, unless considered due to Gilbert's disease or&#xD;
                  leukemic involvement&#xD;
&#xD;
               3. AST, ALT and alkaline phosphatase &lt; 3 times the upper limit of normal, unless&#xD;
                  considered due to leukemic involvement&#xD;
&#xD;
               4. Serum creatinine &lt; 2.0 mg/dL, or creatinine clearance &gt; 40 mL/min based on&#xD;
                  Cockcroft-Gault GFR&#xD;
&#xD;
          -  Absence of unstable cardiac disease defined as myocardial infarction within 6 months,&#xD;
             uncontrolled heart failure, or uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent or&#xD;
             subject's legally authorize representative (LAR) has provided informed consent prior&#xD;
             to any study-specific activities/procedures being initiated when the subject has any&#xD;
             kind of condition that, in the opinion of the investigator, may compromise the ability&#xD;
             of the subject to give written informed consent&#xD;
&#xD;
          -  Women of child-bearing potential and men with partners of child-bearing potential must&#xD;
             agree to use 2 methods of birth control or be surgically sterile, or abstain from&#xD;
             heterosexual activity for the course of the study through 120 days after the last dose&#xD;
             of study medication&#xD;
&#xD;
               1. A woman of child-bearing potential is any female (regardless of sexual&#xD;
                  orientation, having undergone a tubal ligation, or remaining celibate by choice)&#xD;
                  who meets the following criteria:&#xD;
&#xD;
                    1. Has not undergone a hysterectomy or bilateral oophorectomy; or&#xD;
&#xD;
                    2. Has not been naturally postmenopausal for at least 12 consecutive months&#xD;
                       (i.e., has had menses at any time in the preceding 12 consecutive months)&#xD;
&#xD;
               2. Women of child-bearing potential has negative pregnancy test within 72 hours of&#xD;
                  initiating study drug dosing&#xD;
&#xD;
               3. Male subjects must agree to use a latex condom during sexual contact with females&#xD;
                  of childbearing potential even if they have had a successful vasectomy starting&#xD;
                  with the first dose of study therapy through 120 days after the last dose of&#xD;
                  study therapy&#xD;
&#xD;
          -  Leukapheresis, corticosteroid and hydroxyurea are permitted as initial management of&#xD;
             hyperleukocytosis at the investigator's discretion for up to 7 days after starting&#xD;
             study therapy. Hyperleukocytosis is defined as greater than 30k WBC. When possible, a&#xD;
             bone marrow biopsy for screening should be performed prior to the initiation&#xD;
             hyperleukocytosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with Glasdegib or CPX-351&#xD;
&#xD;
          -  Previously treated AML except for initial management of hyperleukocytosis. Treatment&#xD;
             with hypomethylating therapy for MDS is allowable but not since their diagnosis of&#xD;
             AML. No prior treatment with cytarabine or daunorubicin are allowed&#xD;
&#xD;
          -  Concurrent FLT3 mutation that the treating physician deems necessary to treat with&#xD;
             midostaurin, whereas patients with FLT3-mutated AML not treated with midostaurin can&#xD;
             be enrolled. Patients with known Core Binding Factor -t(8;21), inv(16), t(16;16) are&#xD;
             allowed for study participation at the treating investigator's discretion&#xD;
&#xD;
          -  Active CNS or testicular involvement by leukemia; diagnostic lumbar puncture is not&#xD;
             required&#xD;
&#xD;
          -  History of neurologic disorder including but not limited to: prior seizure, epilepsy,&#xD;
             structural brain abnormality, benign brain tumor, stroke, brain injuries, dementia,&#xD;
             movement disorder or other significant CNS abnormalities&#xD;
&#xD;
          -  Baseline QT corrected interval based on Fridericia's formula (QTcF) interval &gt; 450 ms&#xD;
&#xD;
          -  Acute coronary syndrome in the past 12 months, NYHA class III or VI&#xD;
&#xD;
          -  Known history of Wilson's disease or other copper handling disorder&#xD;
&#xD;
          -  History of GI malabsorptive disease&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin, or in situ cervical cancer that has undergone potentially curative therapy&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection (patients who successfully completed&#xD;
             curative hepatitis C therapy can be enrolled)&#xD;
&#xD;
          -  Any uncontrolled infection, active bacterial or viral infection manifesting as fevers&#xD;
             or hemodynamic instability within the past 72 hours&#xD;
&#xD;
          -  Proven active invasive fungal infection&#xD;
&#xD;
          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment&#xD;
&#xD;
          -  Severe or uncontrolled medical disorder that would, in the investigator's opinion,&#xD;
             impair ability to receive study treatment (i.e., uncontrolled diabetes, chronic renal&#xD;
             disease, chronic pulmonary disease or active, uncontrolled infection, psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Current or anticipated use of other investigational agents&#xD;
&#xD;
          -  For patients with prior anthracycline exposure, the cumulative life-time dose should&#xD;
             not exceed 386mg/m2 at the time of study entry (to convert different anthracycline to&#xD;
             daunorubicin-equivalent, see Appendix H for conversion factors)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepa Jeyakumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chao Family Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chao Family Comprehensive Cancer Center University of California, Irvine</last_name>
    <phone>1-877-827-7883</phone>
    <email>ucstudy@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>University of California Irvine Medical</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moores Cancer Center, Unversity of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Wieduwilt, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center, University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepa Jeyakumar, MD</last_name>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Varun Mittal, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Deepa Jeyakumar</investigator_full_name>
    <investigator_title>HS Associate Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Therapy-Related AML</keyword>
  <keyword>AML with MDS related changes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

